JP2003507011A - Ｉｌ−１６拮抗剤 - Google Patents

Ｉｌ−１６拮抗剤

Info

Publication number
JP2003507011A
JP2003507011A JP2001515701A JP2001515701A JP2003507011A JP 2003507011 A JP2003507011 A JP 2003507011A JP 2001515701 A JP2001515701 A JP 2001515701A JP 2001515701 A JP2001515701 A JP 2001515701A JP 2003507011 A JP2003507011 A JP 2003507011A
Authority
JP
Japan
Prior art keywords
seq
antagonist
antagonist peptide
peptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001515701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003507011A5 (https=
Inventor
デイヴィッド エム． センター、
ウィリアム ダブリュー． クリュイクシャンク、
ハーディ コーンフェルド、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Publication of JP2003507011A publication Critical patent/JP2003507011A/ja
Publication of JP2003507011A5 publication Critical patent/JP2003507011A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5446—IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
JP2001515701A 1999-08-05 2000-08-04 Ｉｌ−１６拮抗剤 Pending JP2003507011A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/368,630 US6699466B1 (en) 1999-08-05 1999-08-05 IL-16 antagonist peptides and DNA encoding the peptides
US09/368,630 1999-08-05
PCT/US2000/021317 WO2001010893A2 (en) 1999-08-05 2000-08-04 Il-16 antagonists

Publications (2)

Publication Number Publication Date
JP2003507011A true JP2003507011A (ja) 2003-02-25
JP2003507011A5 JP2003507011A5 (https=) 2006-01-05

Family

ID=23452058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001515701A Pending JP2003507011A (ja) 1999-08-05 2000-08-04 Ｉｌ−１６拮抗剤

Country Status (6)

Country Link
US (6) US6699466B1 (https=)
EP (1) EP1212363A2 (https=)
JP (1) JP2003507011A (https=)
CA (1) CA2378778C (https=)
MX (1) MXPA02001268A (https=)
WO (1) WO2001010893A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides
US8153121B2 (en) * 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
AU2003213963A1 (en) * 2002-04-08 2003-10-27 The John P. Robarts Research Institute Method of treating or preventing autoimmune disease
FR2869528B1 (fr) * 2004-04-28 2007-02-02 Ldr Medical Prothese de disque intervertebral
WO2009129374A2 (en) * 2008-04-18 2009-10-22 Trustees Of Boston University Methods and compositions for preventing adhesion
DK2318020T3 (en) 2008-06-30 2015-11-30 Universitätsklinikum Heidelberg Immunosuppressive blood cells and methods of producing same
SG10201913509YA (en) * 2016-04-28 2020-02-27 Nat Univ Singapore Therapeutic sall4 peptide
CN117860892B (zh) * 2023-12-26 2024-08-06 武汉大学中南医院 Il-16阳性神经元在调节恐惧消退记忆中的作用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510907A (ja) * 1993-05-21 1996-11-19 リサーチ・コーポレイション・テクノロジーズ・インコーポレイテッド リンパ球化学誘引因子およびその用途
WO1997034620A1 (en) * 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
JP2002500889A (ja) * 1998-01-24 2002-01-15 ドイツ連邦共和国 Ｉｌ−１６の変異体、その製造方法およびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5807549A (en) * 1993-05-21 1998-09-15 Research Corporation Technologies, Inc. Lymphocyte chemoattractant factor and uses thereof
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
CA2216755A1 (en) * 1995-03-31 1996-10-03 Brian Lee Buckwalter Peptides with growth promotion properties
DE19649233A1 (de) * 1996-11-28 1998-06-04 Boehringer Mannheim Gmbh Prozessierte Polypeptide mit IL-16 Aktivität, Verfahren zu ihrer Herstellung und Verwendung
US6444202B1 (en) 1996-11-25 2002-09-03 Bundesrepublic Deutschland, Vertreten Durch Den Bundesminister Fur Gesundheit Processed polypeptides with IL-16 activity, processes for their production and their use
JP2001520748A (ja) * 1997-03-24 2001-10-30 ファルマシア・アンド・アップジョン・カンパニー Ｊａｋ２／サイトカイン受容体結合の阻害剤を同定する方法
DE69837542T2 (de) * 1997-04-15 2008-01-31 Merck & Co, Inc. Ldl-rezeptor
EP1066047A4 (en) 1998-03-25 2004-10-13 Mayo Foundation For Medicaledu METHOD AND SUBSTANCES FOR TREATING FLAMMABLE DISEASES
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510907A (ja) * 1993-05-21 1996-11-19 リサーチ・コーポレイション・テクノロジーズ・インコーポレイテッド リンパ球化学誘引因子およびその用途
WO1997034620A1 (en) * 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
JP2002500889A (ja) * 1998-01-24 2002-01-15 ドイツ連邦共和国 Ｉｌ−１６の変異体、その製造方法およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010031225, Ｊ． Ｉｍｍｕｎｏｌ．, 1998, Ｖｏｌ． １６０, ｐｐ．５９４５−５９５４ *
JPN6010031227, Ｉｍｍｕｎｏｇｅｎｅｔｉｃｓ, 1998, Ｖｏｌ． ４７, ｐｐ．３９０−３９７ *

Also Published As

Publication number Publication date
US20030153504A1 (en) 2003-08-14
CA2378778A1 (en) 2001-02-15
US20100008936A1 (en) 2010-01-14
US20070031375A1 (en) 2007-02-08
WO2001010893A3 (en) 2001-08-16
US7608691B2 (en) 2009-10-27
EP1212363A2 (en) 2002-06-12
WO2001010893A2 (en) 2001-02-15
CA2378778C (en) 2011-04-19
US7914778B2 (en) 2011-03-29
US20110207679A1 (en) 2011-08-25
MXPA02001268A (es) 2003-09-10
US20120213790A1 (en) 2012-08-23
US7208149B2 (en) 2007-04-24
US6699466B1 (en) 2004-03-02

Similar Documents

Publication Publication Date Title
EP0529023B1 (en) Therapeutically useful peptides and peptides fragments
US6077680A (en) ShK toxin compositions and methods of use
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
US20120213790A1 (en) Methods of treatment using il-16 antagonist peptides
JPH09501572A (ja) 精製された霊長類ｃｔｌａ−８抗原および関連する試薬
JP2009029833A (ja) Ｃｄ２８／ｃｔｌａ−４阻害性ペプチド模倣物、それらの医薬組成物、およびそれらを使用する方法
RU2337922C9 (ru) ИЗОЛИРОВАННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ НЕЙТРАЛИЗУЮЩЕГО ЭПИТОПА БЕЛКА p17 ВИРУСА ВИЧ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ВАКЦИН, А ТАКЖЕ НЕЙТРАЛИЗУЮЩИЕ АНТИ-p17-АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ УКАЗАННЫЙ НЕЙТРАЛИЗУЮЩИЙ ЭПИТОП
US6011014A (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
AU2005221187B2 (en) Method for inhibiting immune complex formation in a subjetc
AU718442B2 (en) Use of peptide T in the treatment of multiple sclerosis
CA2397267A1 (en) Peptide fragments and uses thereof as type-1 interferon antagonist
US7232801B2 (en) IL-16 antagonists
JP3734855B2 (ja) ペプチド及びその用途
JPH11510792A (ja) 免疫応答を阻害するｃｄ４−誘導ペプチド
AU2011253771B2 (en) Method for inhibiting immune complex formation in a subject
US6803449B2 (en) Nef-attachable protein
JP2680011B2 (ja) Ｔ−４レセプターへの結合を阻害し免疫原として作用する小ペプチド類
JP4171794B2 (ja) ペプチド及びその用途
JP2001503745A (ja) レトロウィルスを阻害するためのペプチド
US7011834B1 (en) Immunomodulating dimers
Tretiakova et al. A rational design approach for developing immunomodulators based on CD4 and CD8

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100907

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110803